Drugs that contain Fluticasone Furoate; Umeclidinium Bromide; Vilanterol Trifenatate
1. Drug name - TRELEGY ELLIPTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE44874 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(5 months from now) | |
| US7498440 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(2 years from now) | |
| US7439393 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(2 years from now) | |
| US7488827 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Dec, 2027
(5 years from now) | |
| CN1976701A | GLAXOSMITHKLINE | Machrs Antagonist |
May, 2012
(10 years ago) | |
| CN1585633A | GLAXOSMITHKLINE | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases |
Sep, 2022
(24 days ago) | |
| CN103288793A | GLAXOSMITHKLINE | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases |
Sep, 2022
(24 days ago) | |
| CN103288793B | GLAXOSMITHKLINE | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases |
Sep, 2022
(24 days ago) | |
| CN101701006B | GLAXOSMITHKLINE | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases |
Sep, 2022
(24 days ago) | |
| CN101701006A | GLAXOSMITHKLINE | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases |
Sep, 2022
(24 days ago) | |
| CN1585633B | GLAXOSMITHKLINE | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases |
Sep, 2022
(24 days ago) | |
| IN212714B | GLAXOSMITHKLINE | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases. |
Sep, 2022
(24 days ago) | |
| IN200400346P2 | GLAXOSMITHKLINE | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases. |
Sep, 2022
(24 days ago) | |
| IN255064B | GLAXOSMITHKLINE | 4-[Hydroxy(Diphenyl)Methyl]-1-(2-[(Phenylmethyl)Oxy]Ethyl}-1-Azoniabicyclo[2.2.2.]Octane Bromide |
Apr, 2025
(2 years from now) | |
| IN200605413P1 | GLAXOSMITHKLINE | Muscarinic Acetylcholine Receptor Antagonists |
Apr, 2025
(2 years from now) | |
| EP2042168A1 | GLAXOSMITHKLINE | Inhalation Formulation Comprising Phenethanolamine Derivatives For The Treatment Of Respiratory Diseases |
Sep, 2022
(24 days ago) | |
| EP2042168B1 | GLAXOSMITHKLINE | Inhalation Formulation Comprising Phenethanolamine Derivatives For The Treatment Of Respiratory Diseases |
Sep, 2022
(24 days ago) | |
| EP2570128A1 | GLAXOSMITHKLINE | Muscarinic Acetylcholine Receptor Antagonists |
Apr, 2025
(2 years from now) | |
| EP2570128B1 | GLAXOSMITHKLINE | Muscarinic Acetylcholine Receptor Antagonists |
Apr, 2025
(2 years from now) | |
| EP1740177A4 | GLAXOSMITHKLINE | Muscarinic Acetylcholine Receptor Antagonists |
Apr, 2025
(2 years from now) | |
| EP1740177B1 | GLAXOSMITHKLINE | Muscarinic Acetylcholine Receptor Antagonists |
Apr, 2025
(2 years from now) | |
| EP1740177A2 | GLAXOSMITHKLINE | Muscarinic Acetylcholine Receptor Antagonists |
Apr, 2025
(2 years from now) | |
| EP1425001A1 | GLAXOSMITHKLINE | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases |
Sep, 2027
(4 years from now) | |
| EP1425001B1 | GLAXOSMITHKLINE | Phenethanolamine Derivatives For Treatment Of Respiratory Diseases |
Sep, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8309572 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(2 years from now) | |
| US8183257 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Jul, 2025
(2 years from now) | |
| US8511304 | GLAXOSMITHKLINE | Medicament dispenser |
Jun, 2027
(4 years from now) | |
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(5 years from now) | |
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(5 years from now) | |
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(7 years from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(8 years from now) | |
| US11090294 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(8 years from now) | |
| US9750726 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(8 years from now) | |
Treatment: Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via topical application; Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via inhalation; method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via topical application; Method of dispensing a combination medicament product from claimed delivery device, for example for the treatment of asthma or copd; Maintenance treatment of chronic obstructive pulmonary disease (copd) comprising the once per day administration of trelegy ellipta, 100 mcg fluticasone furoate/62.5 mcg umeclidinium/25 mcg vilanterol
Dosage: POWDER;INHALATION
| Strength | Dosage | Availability |
|---|---|---|
| 0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | POWDER;INHALATION | Prescription |
| 0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | POWDER;INHALATION | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.